Biomarkers of Alzheimer's Disease: The Present and the Future
Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders and loss of functional autonomy. AD represents the main cause of dementia and has become a major public health issue. In addition, the number of patients suffer...
Sparad:
| Huvudupphov: | , |
|---|---|
| Materialtyp: | Online |
| Språk: | engelska |
| Utgiven: |
Frontiers Media SA
2021
|
| Ämnen: | |
| Länkar: | 25550 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|
| _version_ | 1869521971512868864 |
|---|---|
| author | Charlotte Elisabeth Teunissen Sylvain Lehmann |
| author_browse | Charlotte Elisabeth Teunissen Sylvain Lehmann |
| author_facet | Charlotte Elisabeth Teunissen Sylvain Lehmann |
| author_sort | Charlotte Elisabeth Teunissen |
| collection | Directory of Open Access Books |
| description | Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders and loss of functional autonomy. AD represents the main cause of dementia and has become a major public health issue. In addition, the number of patients suffering from AD is growing rapidly as the population ages worldwide. Memory impairment is usually the earliest clinical and core symptom of this disease. The diagnosis at a late clinical stage is relatively easy. However, a delay in the diagnosis is damageable for the handling of patients in terms of optimal medical and social care. The actual interest of the scientific head-ways is to optimize the diagnosis in prodromal stage of the disease and to propose personalized therapeutic solutions to individual patients. New revised AD diagnostic criteria include early alteration of cerebrospinal fluid (CSF) biomarkers: decrease of amyloïd peptides (Aß42), and increase in tau and phosphorylated-tau (p-tau) protein concentration. This recognition of CSF biological biomarkers for the diagnosis of AD is a major step towards the “molecular” diagnosis and follow-up of the disease. Many issues are however still subject of debate. This e-book provides a comprehensive overview of the state of the art of fluid biomarkers for AD, e.g. which novel biomarkers should be implemented in clinical practice for diagnosis or for monitoring treatment or side effects, which ones are new for AD or related dementias or what is the potential of peripheral blood markers. Moreover, the e-Book provides practical guidelines how to optimally and efficiently develop and validate novel biomarker assays, and to document and control pre-analytical variation. |
| format | Online |
| id | doab-20.500.12854ir-42248 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-422482024-04-05T12:36:18Z Biomarkers of Alzheimer's Disease: The Present and the Future Charlotte Elisabeth Teunissen Sylvain Lehmann RC321-571 Q1-390 Validation Neurochemistry Dementias biomarkers methods discovery CSF diagnosis Alzheimer Blood thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences Alzheimer disease (AD) is a neurodegenerative disorder characterized by significant cognitive deficits, behavioral changes, sleep disorders and loss of functional autonomy. AD represents the main cause of dementia and has become a major public health issue. In addition, the number of patients suffering from AD is growing rapidly as the population ages worldwide. Memory impairment is usually the earliest clinical and core symptom of this disease. The diagnosis at a late clinical stage is relatively easy. However, a delay in the diagnosis is damageable for the handling of patients in terms of optimal medical and social care. The actual interest of the scientific head-ways is to optimize the diagnosis in prodromal stage of the disease and to propose personalized therapeutic solutions to individual patients. New revised AD diagnostic criteria include early alteration of cerebrospinal fluid (CSF) biomarkers: decrease of amyloïd peptides (Aß42), and increase in tau and phosphorylated-tau (p-tau) protein concentration. This recognition of CSF biological biomarkers for the diagnosis of AD is a major step towards the “molecular” diagnosis and follow-up of the disease. Many issues are however still subject of debate. This e-book provides a comprehensive overview of the state of the art of fluid biomarkers for AD, e.g. which novel biomarkers should be implemented in clinical practice for diagnosis or for monitoring treatment or side effects, which ones are new for AD or related dementias or what is the potential of peripheral blood markers. Moreover, the e-Book provides practical guidelines how to optimally and efficiently develop and validate novel biomarker assays, and to document and control pre-analytical variation. 2021-02-11T09:09:46Z 2021-02-11T09:09:46Z 2018-02-27 16:16:44 2016 book 25550 16648714 9782889450411 https://directory.doabooks.org/handle/20.500.12854/42248 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/Biomarkers_of_Alzheimer_s_Disease_The_Present_and_the_Future/1058#nogo http://journal.frontiersin.org/researchtopic/3289/biomarkers-of-alzheimers-disease-the-present-and-the-future Frontiers Media SA 10.3389/978-2-88945-041-1 10.3389/978-2-88945-041-1 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889450411 218 open access |
| spellingShingle | RC321-571 Q1-390 Validation Neurochemistry Dementias biomarkers methods discovery CSF diagnosis Alzheimer Blood thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences Charlotte Elisabeth Teunissen Sylvain Lehmann Biomarkers of Alzheimer's Disease: The Present and the Future |
| title | Biomarkers of Alzheimer's Disease: The Present and the Future |
| title_full | Biomarkers of Alzheimer's Disease: The Present and the Future |
| title_fullStr | Biomarkers of Alzheimer's Disease: The Present and the Future |
| title_full_unstemmed | Biomarkers of Alzheimer's Disease: The Present and the Future |
| title_short | Biomarkers of Alzheimer's Disease: The Present and the Future |
| title_sort | biomarkers of alzheimer s disease the present and the future |
| topic | RC321-571 Q1-390 Validation Neurochemistry Dementias biomarkers methods discovery CSF diagnosis Alzheimer Blood thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences |
| topic_facet | RC321-571 Q1-390 Validation Neurochemistry Dementias biomarkers methods discovery CSF diagnosis Alzheimer Blood thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSA Life sciences: general issues::PSAN Neurosciences |
| url | 25550 |
| work_keys_str_mv | AT charlotteelisabethteunissen biomarkersofalzheimersdiseasethepresentandthefuture AT sylvainlehmann biomarkersofalzheimersdiseasethepresentandthefuture |